Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 50 results
Filters: First Letter Of Last Name is H  [Clear All Filters]
Found 50 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

H

Haas DW, Koletar SL, Laughlin L, et al. "Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir." J. Acquir. Immune Defic. Syndr.. 2009;50(3):290-3.
Haas DW. "Human genetic variability and HIV treatment response." Curr HIV/AIDS Rep. 2006;3(2):53-8.
Haas DW, Bartlett JA, Andersen JW, et al. "Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration." Clin. Infect. Dis.. 2006;43(6):783-6.
Haas DW, Kwara A, Richardson DM, et al. "Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes." J. Antimicrob. Chemother.. 2014;69(8):2175-82.
Haas DW, Geraghty DE, Andersen J, et al. "Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study." J. Infect. Dis.. 2006;194(8):1098-107.
Haas DW, Mootsikapun P, Ruxrungtham K, Podzamczer D. "Clinical perspectives on human genetic screening to prevent nevirapine toxicity." Per Med. 2012;9(7):773-782.
Halvas EK, Aldrovandi GM, Balfe P, et al. "Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency." J. Clin. Microbiol.. 2006;44(7):2612-4.
Halvas EK, Wiegand A, Boltz VF, et al. "Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients." J. Infect. Dis.. 2010;201(5):672-80.
Hammer SM, Ribaudo H, Bassett R, et al. "A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen." HIV Clin Trials. 2010;11(6):312-24.
C Hare B, Mellors J, Krambrink A, et al. "Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy." Clin. Infect. Dis.. 2008;47(3):421-4.
Harrison T, Miyahara S, Lee A, et al. "Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies." Pain Med. 2013;14(7):1039-47.
Haubrich RH, Riddler SA, Ribaudo H, et al. "Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection." AIDS. 2011;25(18):2269-78.
Haubrich RH, Jiang H, Swanstrom R, et al. "Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359." HIV Clin Trials. 2007;8(2):63-7.
Havers F, Smeaton L, Gupte N, et al. "25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings." J. Infect. Dis.. 2014;210(2):244-53.
Havers FP, Detrick B, Cardoso SW, et al. "Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings." PLoS ONE. 2014;9(4):e95164.
Havlir DV, Kendall MA, Ive P, et al. "Timing of antiretroviral therapy for HIV-1 infection and tuberculosis." N. Engl. J. Med.. 2011;365(16):1482-91.
Healy B, De Gruttola V, Pagano M. "Combining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations." Biometrics. 2007;63(3):742-50.
Healy B, Degruttola V. "Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses." Biostatistics. 2007;8(2):438-52.
Hennig S, Svensson EM, Niebecker R, et al. "Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs." J. Antimicrob. Chemother.. 2016;71(5):1330-40.
Henrich TJ, Ribaudo HJ, Kuritzkes DR. "Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy." Clin. Infect. Dis.. 2010;51(1):93-8.
Henrich TJ, Tsibris AMN, Lewine NRP, et al. "Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate." J. Acquir. Immune Defic. Syndr.. 2010;55(4):420-7.
Henrich TJ, Lewine NRP, Lee S-H, et al. "Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists." Antimicrob. Agents Chemother.. 2012;56(4):1931-5.
Henrich TJ, McLaren PJ, Rao SSP, et al. "Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study." Open Forum Infect Dis. 2014;1(1):ofu018.
Henrich TJ, Hanhauser E, Harrison LJ, et al. "CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2016;213(5):766-70.
Henry K, Katzenstein D, Cherng DWeng, et al. "A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102." J. Acquir. Immune Defic. Syndr.. 2006;42(2):140-8.
Hermes A, Squires K, Fredrick L, et al. "Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women." HIV Clin Trials. 2012;13(6):308-23.
Hitti J, Halvas EK, Zheng L, et al. "Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207." J AIDS Clin Res. 2014;5(11).
Hitti J, Andersen J, McComsey G, et al. "Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084." Am. J. Obstet. Gynecol.. 2007;196(4):331.e1-7.
Hochreiter J, Lapham J, Wong-Staal F, et al. "ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection." Antivir. Ther. (Lond.). 2013;18(3):329-36.
Hoffman RM, Jamieson BD, Bosch RJ, et al. "Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals." J. Clin. Immunol.. 2011;31(5):873-81.

Pages